There are moments in capital markets that read less like transactions and more like declarations. Singapore’s DBS Group — the largest bank in Southeast Asia — has just made one. Its first-ever equity capital markets mandate in India comes attached to one of the most anticipated healthcare listings in the subcontinent’s history: the roughly $1 billion IPO of Manipal Health Enterprises, filed with SEBI on March 24, 2026. For anyone tracking the DBS India IPO push, or the broader maturation of India ECM 2026, this moment carries weight far beyond the deal ticket.

This is not merely a bank chasing fees. It is a strategic repositioning — DBS signalling, loudly and deliberately, that India’s equity capital markets are no longer a peripheral opportunity to be observed from Singapore. They are, the bank has decided, a home market.

Why the Manipal Health IPO Is the Perfect Debut Vehicle

Manipal Health Enterprises filed draft papers for an initial public offering that could become India’s largest listing by a hospital operator Bloomberg — a distinction that carries both commercial and symbolic gravity. The IPO combines a fresh issue of ₹8,000 crore alongside an offer for sale of up to 43.23 million equity shares by promoters, with proceeds earmarked in part for repayment of outstanding borrowings and for acquiring a minority stake in Sahyadri Hospitals, a subsidiary of Manipal Health Enterprises. Sujatawde

The valuation ambition is striking. At a potential market capitalisation of up to $13 billion, Manipal Health would immediately rank among the most valuable hospital chains on any Asian exchange. As of September 30, 2025, the company operated 38 hospitals — 48 on a pro forma basis — with over 10,700 licensed beds across 14 states and union territories, making it the largest pan-India multispecialty hospital network by bed capacity and the second largest by number of hospitals, according to a CRISIL report cited in the DRHP. Business Standard

The clinical profile is equally compelling. Manipal’s specialisation in what its DRHP calls “CONGO-R” disciplines — cardiac sciences, oncology, neurosciences, gastrosciences, orthopaedics, and renal sciences — positions it squarely at the intersection of India’s two most powerful demographic forces: an ageing middle class and a rapidly expanding demand for tertiary and quaternary care that public hospitals cannot absorb.

This is the deal DBS chose to announce itself. The choice was not accidental.

The Temasek Thread: Strategic Symbiosis at the Heart of the DBS-Manipal Story

To understand DBS’s first ECM mandate India, one must first understand Temasek Holdings — the Singaporean sovereign wealth fund that threads through this transaction like a golden wire.

Temasek Holdings is the largest shareholder in both Manipal Health Enterprises and DBS Group. Bloomberg That single fact transforms what might otherwise appear to be a routine banking mandate into something considerably more strategic. DBS is not merely a hired underwriter here; it is, in a meaningful sense, a co-owner of the asset it is helping to float. The alignment of interests between banker, shareholder, and state investor creates a tri-party dynamic that is unusual even by the standards of Asia’s interconnected capital markets.

Former DBS Chief Executive Piyush Gupta, who retired from the bank last year, now serves as chairman of Temasek International’s Indian operations Medical Buyer — adding a further layer of institutional continuity and personal relationship capital to the Singapore-India corridor. In the world of investment banking, relationships move mandates. The relational architecture here is unusually dense.

DBS has been consistently positive about India’s growth trajectory and demonstrated willingness to commit capital to the market — most notably by taking over Lakshmi Vilas Bank in 2020, the first time Indian authorities turned to a foreign lender to rescue a struggling local rival. Yahoo! That intervention was, in retrospect, the first visible chapter of a longer India strategy. The Manipal mandate is the latest — and most public — expression of it.

DBS Joins India IPO Space: The Mechanics of a New Platform

The book-running lead managers for the Manipal Health IPO are Kotak Mahindra Capital, Axis Capital, Goldman Sachs (India) Securities, Jefferies India, J.P. Morgan India, UBS Securities India, and DBS Bank India Limited. Sujatawde That lineup reads like a who’s-who of global and domestic ECM capability — and DBS earns its place at the table not through legacy relationships in Indian equity markets, but through a combination of institutional credibility, Temasek synergy, and the deliberate construction of a new platform.

A DBS spokesperson confirmed that the bank has expanded into equity capital markets under its merchant banking licence in India and now has a fully operational investment banking platform in the country. Yahoo! The bank holds, in its own words, “strong conviction in the long-term prospects, continuous evolution and global integration of the Indian capital markets,” describing the expansion as a “natural progression” that reinforces its long-term commitment to a market where it already operates corporate, consumer, and wealth banking. Medical Buyer

Crucially, this is not a remote operation. Sanjog Kusumwal, an ECM banker from DBS’s Singapore operations, will relocate to India to lead investment banking and build out the onshore ECM franchise, while also expanding fixed-income origination. Medical Buyer The commitment of human capital — moving people, not just mandates — is the clearest signal that DBS is building for the long term, not harvesting a cyclical boom.

The DBS merchant banking licence India ECM framework also opens doors beyond equity. The bank has signalled plans to offer a comprehensive suite of investment banking services across debt and equity, using its Asian distribution network to connect Indian issuers with institutional capital across the region. In practice, this means Indian corporates eyeing pre-IPO placements, convertible bonds, or cross-border capital will have a new, Singapore-anchored alternative to the established bulge-bracket order.

India IPO Market 2026: From Boom to Structural Ascent

The timing of DBS’s entry is no coincidence. India’s primary markets have undergone a fundamental transformation in recent years — moving from a domestically driven, fee-compressed environment to one that commands global attention and, increasingly, global-grade economics.

India’s fundraising activity surged to more than $22 billion last year, ranking the country as the fourth-largest IPO market globally. Investment banks in India earned a record $417 million in underwriting fees for initial public offerings last year, according to LSEG data. The average fee paid to bankers for IPOs rose to 1.86% of deal value, up from 1.67% a year earlier. Medical Buyer

Those numbers matter enormously. For years, one of the persistent complaints from international banks about India was the fee compression endemic to its ECM — deals priced at margins that made the economics of building a full platform difficult to justify. That dynamic is shifting. As deal sizes grow and issuers become more willing to pay for global distribution, the record India IPO underwriting fees 2025 environment is transforming the competitive calculus for everyone from boutique advisory firms to Singapore’s largest bank.

Proceeds from IPOs in 2026 may reach a record for a third consecutive year, supported by a strong pipeline and robust investor demand, according to investment bankers from Goldman Sachs and JPMorgan. Medical Buyer The pipeline includes marquee names — Jio, NSE, and a growing cohort of healthcare and consumer tech issuers — that would make any ECM franchise salivate. The primary market in early 2026 has been relatively quiet, but the absence of large issues in the ₹5,000–8,000 crore range makes Manipal’s filing all the more significant as a potential catalyst for renewed momentum. News9live

India Healthcare IPO: Why the Sector Is Attracting Global Capital

The India healthcare IPO thesis deserves its own analysis, because it is not simply a story about one company. It is a story about structural demand that no amount of macroeconomic volatility can easily reverse.

India’s demographic dividend — over a billion people, a rapidly expanding middle class, falling infant mortality, and rising chronic disease burden — creates a healthcare demand curve that is, in the language of investors, extremely durable. The country’s private hospital sector has consolidated aggressively over the past decade, with players like Manipal, Apollo, Fortis, and Aster racing to acquire regional chains, build specialty towers, and deploy AI-assisted diagnostic tools that compress cost per procedure while expanding throughput.

Manipal’s acquisition of Sahyadri Hospitals — funded in part by the IPO proceeds — is a textbook example of this consolidation logic. Sahyadri is a well-regarded Maharashtra-based chain with strong positioning in Pune, one of India’s fastest-growing cities. Adding it to Manipal’s network expands the company’s western India footprint and diversifies revenue geography ahead of the public listing — a classic pre-IPO value-creation move that sophisticated institutional investors will price favourably.

The broader sector tailwind is reflected in valuations. Indian hospital stocks have traded at premium multiples relative to regional peers, reflecting both the scarcity of quality listed healthcare assets and the market’s confidence in long-term earnings visibility. A successful Manipal listing — at a potential $13 billion valuation — would reset the sector benchmark and likely accelerate further healthcare listings in 2026 and beyond.

The Singapore-India Financial Corridor: A Bigger Story

Zoom out further, and the Singapore bank enters Indian equity capital markets narrative becomes part of an even larger geopolitical-financial story: the deepening of the Singapore-India corridor as a structural feature of Asian capital flows.

Singapore has long served as India’s most important foreign direct investment gateway. The bilateral investment treaty, the two countries’ shared Commonwealth legal heritage, and Singapore’s role as Asia’s premier financial hub have made it the default routing point for capital entering and exiting India. What has been missing — until now — is a major Singapore-headquartered bank playing a meaningful role in India’s domestic equity markets, not just in offshore financing or private credit.

DBS’s entry changes that. It is, in effect, a Singapore bank entering Indian equity capital markets not as a curiosity or a strategic experiment, but as a fully capitalised, licensed, and staffed market participant. The implications for other Singapore-based institutions — including OCBC and UOB, both of which have India presences but lack DBS’s scale — will be worth monitoring. If DBS demonstrates that the economics of an India ECM franchise can justify the investment, others will follow.

For India, meanwhile, the arrival of another globally networked bank adds depth to its underwriting ecosystem and expands the pool of international investors accessible through bookbuilding. This is not trivial: as Indian IPOs grow in size and ambition, the ability to distribute paper to sovereign wealth funds, European long-only managers, and US institutional investors becomes increasingly important. DBS’s Asian distribution network — with particularly strong reach into Southeast Asian sovereign and institutional capital — fills a gap that neither the domestic brokerages nor the pure-play US bulge brackets fully address.

Risks on the Horizon: What Could Derail the Narrative

No analysis of India’s IPO boom would be complete without a frank accounting of the risks. Three stand out.

Global sentiment volatility. India’s retail investor base has provided extraordinary domestic liquidity support for IPOs over the past three years. But institutional demand — particularly from foreign portfolio investors — remains sensitive to global risk appetite, US Federal Reserve policy, and dollar strength. A sharp global risk-off move could see FPI allocations to India compressed precisely as a large pipeline of issuances hits the market.

Valuation gaps. The $13 billion valuation aspiration for Manipal Health implies multiples that will require a clean, well-executed roadshow and strong early institutional demand to sustain. Healthcare valuations globally have come under pressure as interest rates remained elevated longer than markets anticipated. Indian hospital stocks’ premium to global peers is structurally justified — but not infinitely elastic.

Execution risk for DBS itself. Building an India ECM franchise from scratch while co-managing a $1 billion deal is an ambitious sequencing. The bank’s success in the Manipal transaction will be closely watched by both issuers and regulators as a proof-of-concept for its broader India investment banking ambitions. A stumble here would be costly — reputationally if not financially.

What to Watch

For investors and market watchers, the next 90 days are pivotal:

• SEBI approval timeline: The regulator’s review of the Manipal DRHP will set the clock for the eventual IPO launch. A swift green light from SEBI would signal regulatory confidence in the filing’s quality and the deal structure.
• Pre-IPO placement: A pre-IPO placement of up to ₹1,600 crore is under consideration; if it materialises, the size of the fresh issue will be reduced commensurately News9live — a useful gauge of institutional appetite before the public offering opens.
• DBS’s next India mandate: The bank has signalled a comprehensive platform build. Watch for whether Manipal is a one-off or the first of a rapid sequence of ECM mandates — particularly in sectors where DBS’s corporate banking relationships are deepest, such as infrastructure, renewables, and financial services.
• Competitive response: How do Goldman, JPMorgan, and the domestic heavyweights respond to a newly emboldened DBS competing for mandates? Fee dynamics and the composition of future bookrunner syndicates will be telling.
• India ECM 2026 pipeline: The Manipal filing may well unlock the dam on a series of large healthcare and consumer deals that have been waiting for a market window. Monitor the SEBI DRHP filing tracker through April and May for accelerating activity.

India’s equity capital markets have spent two decades maturing. The arrival of DBS — disciplined, well-capitalised, and strategically motivated — is not just a new entrant in a lucrative league table. It is confirmation that the world’s most sophisticated financial institutions now view India’s primary markets not as emerging-market frontier territory, but as a core global venue. That recognition, more than any single deal, is the real story of March 2026.